S-1 Monotherapy as Second-line Treatment for Advanced Pancreatic Cancer after Gemcitabine Failure

作者：Akiko Todaka, Akira Fukutomi, Narikazu Boku, Y. Onozawa, S. Hironaka, Haruna Yasui, Kentaro Yamazaki, K. Taku, Nozomu Machida, Takashi Sakamoto, Hideharu Tomita · 发表于：Japanese Journal of Clinical Oncology · 年份：2010 · DOI：10.1093/jjco/hyq005 · 被引用次数：31 · 研究领域：Pancreatic and Hepatic Oncology Research、Pancreatitis Pathology and Treatment、Cholangiocarcinoma and Gallbladder Cancer Studies

OBJECTIVE: No standard salvage chemotherapy regimen has been established for patients with advanced pancreatic cancer after failure of gemcitabine-based treatment. Although a Phase II study of S-1 monotherapy was conducted in patients with gemcitabine-refractory advanced pancreatic cancer, the number of patients enrolled was small. METHODS: We retrospectively reviewed 84 consecutive patients who received S-1 monotherapy as a second-line treatment after gemcitabine failure at the Shizuoka Cancer Center between May 2004 and April 2008. The selection criteria in this study were age 20-75 years, ECOG performance status